Quick Answer
Maze Therapeutics, Inc. reported Operating Income of -$142.90 million for fiscal year 2025.
Maze Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$142.90M | -348.1% |
| 2024 | $57.59M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$32.97M | -36.1% | +9.6% |
| June 30, 2025 | -$36.47M | -126.1% | -3.0% |
| March 31, 2025 | -$35.40M | -26.4% | -46.1% |
| September 30, 2024 | -$24.23M | — | -117.4% |
| June 30, 2024 | $139.56M | — | +598.2% |
| March 31, 2024 | -$28.01M | — | — |
- Maze Therapeutics, Inc. showed a decrease of -348.1% in Operating Income compared to the prior fiscal year.
- Over the 2024–2025 period, Maze Therapeutics, Inc.’s operating income has declined by 348.1% (from $57.59 million to -$142.90 million).
- The most recent figure is from Maze Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: